title: The natural products beauveriolide I and III: a new class of beta-amyloid-lowering compounds.
abstract: Attacking Alzheimer's by ACAT: The aggregation of beta-amyloid peptides, especially Abeta(42), into senile plaques is a hallmark of Alzheimer's disease (AD). We show that the fungal natural products beauveriolides I and III can potently decrease Abeta secretion from cells expressing human amyloid precursor protein; this offers a potential new scaffold for the development of compounds with proven bioavailability for the treatment of AD.
authors.affiliation: The Scripps-Oxford Laboratory, Oxford Glycobiology Institute, Department of Biochemistry, University of Oxford, South Parks Road, Oxford, OX1 3QU, UK.
authors.forename: Daniel P
authors.initials: DP
authors.lastname: Witter
authors.forename: Yanping
authors.initials: Y
authors.lastname: Chen
authors.forename: Joseph K
authors.initials: JK
authors.lastname: Rogel
authors.forename: Grant E
authors.initials: GE
authors.lastname: Boldt
authors.forename: Paul
authors.initials: P
authors.lastname: Wentworth
mesh_terms: D000544:Alzheimer Disease / Q000188:drug therapy; D016229:Amyloid beta-Peptides / Q000378:metabolism*; D000818:Animals; D016466:CHO Cells; D002460:Cell Line; D006224:Cricetinae; D003412:Cricetulus; D047630:Depsipeptides / Q000138:chemical synthesis / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology*; D006801:Humans; D058225:Plaque, Amyloid / Q000378:metabolism
chemical_list: D016229:Amyloid beta-Peptides; D047630:Depsipeptides; C013833:beauverolides